Vaccine Weekly

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly


We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Emergent BioSolutions Inc.

Emergent BioSolutions Reports Financial Results for Third Quarter and First Nine Months of 2008

Total revenues for the third quarter and nine months of 2008 were $56.6 million and $142.8 million, respectively, an increase of 30 percent and 53 percent, respectively, over the prior year periods. Net income for the third quarter and nine months of 2008 was $10.4 million or $0.35 per share, and $19.2 million or $0.65 per share, respectively, in comparison to net income of $2.8 million or $0.10 per share, and a net loss of $4.8 million or $0.17 per share for the comparable periods in 2007. Such performance was primarily driven by growth...

• View Other Issues of Vaccine Weekly
  
• View Other NewsRx Publications